Norio Nakatsuji's Biography

Norio Nakatsuji, Chief Advisor, Stem Cell & Device Laboratory, Inc. (SCAD); Professor Emeritus, Kyoto University

Prof. Norio Nakatsuji is Professor Emeritus of Kyoto University and Founding Director of its Institute for Integrated Cell-Material Sciences. He is also Chief Advisor of Stem Cell & Device Laboratory, Inc. and CEO of Kyoto Stem Cell Innovation, Inc.

Prof. Nakatsuji is a graduate from Kyoto University. He obtained postdoctoral training in Sweden, USA and UK. He became a professor at National Institute of Genetics in 1991. In 1999, He moved to the Institute for Frontier Medical Sciences at Kyoto University and became its director from 2003 to 2007. His laboratory established monkey ES cell lines in 2000 and human ES cell lines in 2003, which were distributed to other scientists. He is also a scientific founder of a start-up company, ReproCELL, Inc., which accomplished successful IPO in 2013

From 2007, he was the founding director of Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS), an institute which aims to advance cross-disciplinary research and technological innovation, including stem cell R&D utilizing chemical compounds and functional materials. He became a Professor Emeritus of Kyoto University in 2015. He took a leadership in government-supported stem cell projects of industry-academia collaboration.

In 2014, he founded two start-up companies, Kyoto Stem Cell Innovation, Inc. (SCI) and Stem Cell & Device Laboratory, Inc. (SCAD). He is a Director and Chief Advisor of SCAD, which is developing innovative products by integration of human pluripotent stem cell (ESC/iPSC) technology and nanotechnology/micro-engineering for drug screening and drug safety assay as well as cell therapy.

3D Cell-Material Micro-Tissue Devices in Application of ES/iPS Cells for Drug Screening/Toxicology and Cell Therapy

Monday, 10 July 2017 at 16:30

Add to Calendar ▼2017-07-10 16:30:002017-07-10 17:30:00Europe/London3D Cell-Material Micro-Tissue Devices in Application of ES/iPS Cells for Drug Screening/Toxicology and Cell TherapyStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

SCAD is a start-up company founded in 2014 based on the integration of stem cell technology and nanotechnology/micro-engineering developed at Kyoto University. We are currently focusing on the iPSC-derived cardiomyocytes, with possible addition of neurons and hepatocytes. Cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) are promising materials for drug screening/toxicology and cell therapy. However, there are two major issues: immaturity of hPSC-CMs and instability of cardiac cellular function. To overcome these issues, we use two technologies: the robust cardiac differentiation method and aligned nanofibers as a culture scaffold. Our cardiac differentiation method can efficiently generate cardiomyocytes from any hPSC lines under cytokine-free defined condition. The hPSC-CMs seeded on nanofiber scaffolds formed 3D multilayered structures (Micro-Tissues), which show upregulated expression of cardiac maturation marker genes and enhanced and stable cardiac cell functions. Our micro-tissue devices are easy to handle and highly useful for drug screening/toxicology assays.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors